Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528641 | 0.92 | NR1H2 (0.69) | ESR2NR1H2NPC1RAB9AMAPT | |
| SCHEMBL30643119 | 0.92 | ESR2 (0.70) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL1074833 | 0.92 | NR1H2 (0.69) | ESR2NR1H2NPC1RAB9AMAPT | |
| SCHEMBL2568732 | 0.92 | ESR2 (0.70) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL3479626 | 0.87 | ESR2 (0.56) | ESR2NR1H2NPC1RAB9AUSP2 | |
| SCHEMBL15331570 | 0.85 | NR1H2 (0.59) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL2558810 | 0.85 | ESR2 (0.60) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL19585056 | 0.83 | ESR2 (0.54) | ESR2NR1H2NPC1RAB9AHDAC6 | |
| SCHEMBL2132877 | 0.82 | ESR2 (0.84) | ESR2NR1H2NPC1RAB9AUSP2 | |
| SCHEMBL7868104 | 0.82 | ESR2 (0.63) | ESR2NR1H2NPC1RAB9AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2937344-B1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9447074-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2937344-A1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Glaxo Group Limited (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-20150166508-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| EP-2683709-B1 | PYRIDINYL- AND PYRAZINYL-METHYLOXY-ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | GLAXO GROUP LTD (GB) | 2015-05-06 | — | — | EP | disclosed |
| US-8993560-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK J | 2007-12-27 | — | — | US | disclosed |
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
| EP-1778643-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-05-02 | — | — | EP | disclosed |
| EP-1735299-A1 | TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006018260-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H 3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2005097778-A1 | TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
| EP-1572215-A1 | BENZO[D]AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056369-A1 | BENZO ‘ D!AZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166508-A1 | NOVEL COMPOUNDS | SYK, NFATC1, BTK | ESR2 3007/4885NR1H2 1423/4885NPC1 3002/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | ESR2 1181/4885NR1H2 665/4885NPC1 419/4885 |
| US-20160355505-A1 | NOVEL COMPOUNDS | SYK, NFATC1, BTK | ESR2 3007/4885NR1H2 1423/4885NPC1 3002/4885 |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | ESR2 1520/4885NR1H2 463/4885NPC1 2377/4885 |
| US-20070299056-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, TPH1, GRIN2B | ESR2 2016/4885NR1H2 863/4885NPC1 345/4885 |
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | ESR2 938/4885NR1H2 354/4885NPC1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.